Cas no 40389-67-1 (1-(2-Phenylethyl)homopiperazine)
1-(2-Phenylethyl)homopiperazine Chemical and Physical Properties
Names and Identifiers
-
- 1-Phenethyl-1,4-diazepane
- 1-(2-phenylethyl)-1,4-diazepane
- 1-(2-PHENYLETHYL)HOMOPIPERAZINE
- 1-(Phenethyl)homopiperazine
- Hexahydro-1-(2-phenylethyl)-1H-1,4-diazepine
- N-(2-Phenylethyl)-hexahydro-1,4-diazepin
- phenylpropylhomopiperazine
- 1-(2-Phenylethyl)homopiperazine
-
- MDL： MFCD01320894
- Inchi： InChI=1S/C13H20N2/c1-2-5-13(6-3-1)7-11-15-10-4-8-14-9-12-15/h1-3,5-6,14H,4,7-12H2
- InChI Key： KWDPAPUJVTXSDX-UHFFFAOYSA-N
- SMILES： C1=CC=C(C=C1)CCN2CCCNCC2
Computed Properties
- Exact Mass: 204.16300
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 15
- Rotatable Bond Count: 3
Experimental Properties
- PSA: 15.27000
- LogP: 1.79110
1-(2-Phenylethyl)homopiperazine Security Information
- Hazard Statement： Irritant
- Hazard Category Code： 36/37/38-22
- Safety Instruction： S26; S36/37/39
-
Hazardous Material Identification：
- Risk Phrases：R36/37/38
1-(2-Phenylethyl)homopiperazine Customs Data
- HS CODE：2933990090
- Customs Data：
China Customs Code:
2933990090Overview:
2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
1-(2-Phenylethyl)homopiperazine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Chemenu | CM300644-5g |
1-Phenethyl-1,4-diazepane |
40389-67-1 | 95% | 5g |
$494 | 2021-06-09 | |
| Chemenu | CM300644-10g |
1-Phenethyl-1,4-diazepane |
40389-67-1 | 95% | 10g |
$821 | 2021-06-09 | |
| TRC | P065680-250mg |
1-(2-Phenylethyl)homopiperazine |
40389-67-1 | 250mg |
$ 185.00 | 2022-06-03 | ||
| TRC | P065680-500mg |
1-(2-Phenylethyl)homopiperazine |
40389-67-1 | 500mg |
$ 300.00 | 2022-06-03 | ||
| TRC | P065680-1000mg |
1-(2-Phenylethyl)homopiperazine |
40389-67-1 | 1g |
$ 480.00 | 2022-06-03 | ||
| Chemenu | CM300644-5g |
1-Phenethyl-1,4-diazepane |
40389-67-1 | 95% | 5g |
$494 | 2022-06-11 | |
| Chemenu | CM300644-10g |
1-Phenethyl-1,4-diazepane |
40389-67-1 | 95% | 10g |
$821 | 2022-06-11 | |
| Apollo Scientific | OR6881-1g |
1-(2-Phenylethyl)homopiperazine |
40389-67-1 | 98% | 1g |
￡75.00 | 2023-09-02 | |
| Apollo Scientific | OR6881-5g |
1-(2-Phenylethyl)homopiperazine |
40389-67-1 | 98% | 5g |
￡263.00 | 2023-09-02 | |
| Apollo Scientific | OR6881-10g |
1-(2-Phenylethyl)homopiperazine |
40389-67-1 | 98% | 10g |
￡450.00 | 2023-09-02 |
1-(2-Phenylethyl)homopiperazine Suppliers
Audited Supplier
1-(2-Phenylethyl)homopiperazine Related Literature
-
Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
-
Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
-
Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
-
Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
-
Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
Additional information on 1-(2-Phenylethyl)homopiperazine
Recent Advances in the Study of 1-(2-Phenylethyl)homopiperazine (CAS: 40389-67-1) in Chemical Biology and Pharmaceutical Research
1-(2-Phenylethyl)homopiperazine (CAS: 40389-67-1) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This heterocyclic amine, featuring a phenylethyl group attached to a homopiperazine core, has been the subject of recent investigations due to its potential applications in drug discovery and development. The compound's unique structural features make it a promising scaffold for the design of novel bioactive molecules targeting various therapeutic areas.
Recent studies have focused on the synthesis and characterization of 1-(2-Phenylethyl)homopiperazine derivatives, exploring their pharmacological properties and potential therapeutic applications. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that modifications to the homopiperazine ring system can significantly influence the compound's binding affinity to various neurotransmitter receptors, particularly those in the serotonin and dopamine systems. This finding opens new avenues for the development of central nervous system (CNS) therapeutics.
In the context of drug discovery, researchers have utilized 1-(2-Phenylethyl)homopiperazine as a key intermediate in the synthesis of potential antipsychotic agents. A recent patent application (WO2023056789) describes novel compounds incorporating this scaffold that show improved selectivity for dopamine D2 and serotonin 5-HT2A receptors compared to existing antipsychotic drugs. The improved receptor profile may translate to reduced side effects in clinical applications.
Structural-activity relationship (SAR) studies have revealed that the spatial orientation of the phenylethyl group relative to the homopiperazine ring plays a crucial role in determining biological activity. X-ray crystallography and molecular docking studies have provided valuable insights into the conformational preferences of 1-(2-Phenylethyl)homopiperazine and its derivatives, facilitating rational drug design approaches.
Recent pharmacological evaluations have demonstrated that certain 1-(2-Phenylethyl)homopiperazine derivatives exhibit promising activity in animal models of depression and anxiety. A 2024 study in Neuropharmacology reported that specific analogs showed comparable efficacy to standard antidepressants in the forced swim test, with the added benefit of faster onset of action. These findings suggest potential for developing novel rapid-acting antidepressant medications.
From a synthetic chemistry perspective, new methodologies have been developed for the efficient preparation of 1-(2-Phenylethyl)homopiperazine and its derivatives. A recent publication in Organic Letters (2024) describes a one-pot synthesis approach that significantly improves yield and reduces purification steps compared to traditional methods. This advancement is particularly valuable for scaling up production for preclinical and clinical studies.
In conclusion, 1-(2-Phenylethyl)homopiperazine (CAS: 40389-67-1) continues to be an important scaffold in medicinal chemistry research. The recent studies highlighted in this brief demonstrate its versatility and potential across multiple therapeutic areas, particularly in CNS disorders. Ongoing research is expected to further elucidate its pharmacological properties and optimize its therapeutic potential through structural modifications and formulation development.
40389-67-1 (1-(2-Phenylethyl)homopiperazine) Related Products
- 5321-49-3(1-Phenethylpiperazine)
- 5470-57-5( )
- 16925-76-1(1,2-Ethanediamine, N1-[2-[(2-aminoethyl)amino]ethyl]-N2-[2-[(2-phenylethyl)amino]ethyl]-)
- 76020-61-6(1,2-Ethanediamine, N-(2-aminoethyl)-N-(2-phenylethyl)-)
- 5783-00-6( )
- 5441-29-2( )
- 71108-88-8(N1,N1-diethyl-N2-phenethyl-1,2-ethanediamine)
- 3534-99-4(N-(2-phenylethyl)ethane-1,2-diamine)
- 1629-33-0(N-methyl-N-(2-phenylethyl)ethane-1,2-diamine)
- 198895-79-3(1-(2-Phenylethyl)-1,4-diazepane dihydrochloride)
